Psoriasis vulgaris (PV) is one of the leading and most common forms of dermatoses. The development mechanism of PV is multifaceted and in large measure is associated with significant changes in various components of immune system, which manifests itself in the development of both local and systemic inflammation. Cellular metabolic disorders in PV play a large role in the disease course, which leads to a change in the oxidation-reduction potential of cells and tissues, as well as to excessive activation of free-radical oxidation. As a consequence, the course of PV is often accompanied by the development of many concomitant chronic diseases. Nevertheless, the use of local therapy — topical glucocorticosteroids (tGCS), calcineurin inhibitors, vitamin D analogues, keratolytics and combination therapy occupies a leading place in the treatment of patients with uncomplicated PV and without articular manifestations. At the same time, the use of therapy aimed at correcting systemic pathological changes in PV is limited and little studied to date. The study of the effectiveness of systemic cytoprotective therapy and topical combination therapy conjunction application is relevant due to the diversity of approaches to PV treatment. The use of hepatic cytoprotective drugs in the PV treatment strategy can improve the clinical effect by correction of cellular abnormalities in PV, namely by means of acceleration of free-radical oxidation products degradation and normalization of oxidative-reduction potential of blood and tissues. In the frame of topical therapy, the addition of keratolytics is able to potentiate the positive effects of tGCS, which is especially effective in case of pronounced desquamation. The clinical effectiveness of systemic hepatic cytoprotective therapy (succinic acid, meglumine, inosine, nicotinamide, methionine, folic acid) together with the combination topical therapy based on tGCS and salicylic acid in dosage forms of ointment and lotion in PV is shown based on clinical cases’ demonstration.